Total Payments
$10,276
2024 Payments
$1,872
Companies
24
Transactions
468
Medicare Patients
3,284
Medicare Billing
$244,867
Payment Breakdown by Category
Food & Beverage$10,257 (99.8%)
Education$19.06 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $10,257 | 466 | 99.8% |
| Education | $19.06 | 2 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $2,920 | 133 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $2,250 | 112 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,631 | 73 | $0 (2024) |
| GENZYME CORPORATION | $624.40 | 30 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $444.62 | 18 | $0 (2024) |
| Genentech USA, Inc. | $409.44 | 18 | $0 (2022) |
| E.R. Squibb & Sons, L.L.C. | $351.21 | 14 | $0 (2022) |
| Takeda Pharmaceuticals U.S.A., Inc. | $229.91 | 10 | $0 (2024) |
| Mylan Specialty L.P. | $203.16 | 9 | $0 (2024) |
| Amgen Inc. | $186.40 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,872 | 82 | GlaxoSmithKline, LLC. ($469.28) |
| 2023 | $1,257 | 58 | GlaxoSmithKline, LLC. ($435.01) |
| 2022 | $1,567 | 69 | GlaxoSmithKline, LLC. ($415.57) |
| 2021 | $1,423 | 67 | GlaxoSmithKline, LLC. ($472.09) |
| 2020 | $1,115 | 56 | GlaxoSmithKline, LLC. ($500.76) |
| 2019 | $1,115 | 55 | GlaxoSmithKline, LLC. ($354.32) |
| 2018 | $1,110 | 47 | GlaxoSmithKline, LLC. ($217.18) |
| 2017 | $817.73 | 34 | AstraZeneca Pharmaceuticals LP ($347.25) |
All Payment Transactions
468 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $27.50 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2024 | Amgen Inc. | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $22.22 | General |
| Category: Inflammation | ||||||
| 12/05/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 12/03/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Immunology | ||||||
| 11/21/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 11/14/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Respiratory | ||||||
| 11/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.00 | General |
| Category: Immunology | ||||||
| 11/07/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 10/31/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 10/30/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: Immunology | ||||||
| 10/28/2024 | AstraZeneca Pharmaceuticals LP | TEZSPIRE (Biological) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: Respiratory | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $29.67 | General |
| Category: Respiratory | ||||||
| 10/17/2024 | Janssen Pharmaceuticals, Inc | UPTRAVI (Drug) | Food and Beverage | In-kind items and services | $20.60 | General |
| Category: Cardiology | ||||||
| 10/15/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Immunology | ||||||
| 10/10/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 10/02/2024 | Mylan Specialty L.P. | YUPELRI (Drug) | Food and Beverage | In-kind items and services | $29.42 | General |
| Category: Anticholinergics, Inhaled | ||||||
| 10/02/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $18.73 | General |
| Category: Respiratory | ||||||
| 09/26/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.50 | General |
| Category: Immunology | ||||||
| 09/25/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | OFEV (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 09/18/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
| 09/17/2024 | Merck Sharp & Dohme LLC | WINREVAIR (Biological) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: CARDIOVASCULAR | ||||||
| 09/16/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.94 | General |
| Category: Respiratory | ||||||
| 09/13/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $9.24 | General |
| Category: IMMUNOLOGY | ||||||
| 09/12/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $25.00 | General |
| Category: RESPIRATORY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 748 | 1,251 | $97,025 | $52,958 |
| 2022 | 12 | 975 | 1,874 | $130,214 | $81,361 |
| 2021 | 13 | 842 | 1,526 | $79,497 | $58,096 |
| 2020 | 15 | 719 | 1,195 | $77,530 | $52,451 |
Total Patients
3,284
Total Services
5,846
Medicare Billing
$244,867
Procedure Codes
49
All Medicare Procedures & Services
49 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 127 | 295 | $39,435 | $28,028 | 71.1% |
| 94375 | Test to measure rate of airflow | Office | 2023 | 134 | 265 | $26,500 | $7,745 | 29.2% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 104 | 107 | $6,420 | $4,611 | 71.8% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2023 | 101 | 104 | $5,200 | $3,611 | 69.4% |
| 94200 | Test to measure largest amount of air breathed in an out | Office | 2023 | 134 | 265 | $7,950 | $3,082 | 38.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 28 | 28 | $4,200 | $2,484 | 59.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 18 | 21 | $2,625 | $1,304 | 49.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2023 | 20 | 25 | $1,875 | $1,076 | 57.4% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2023 | 82 | 141 | $2,820 | $1,018 | 36.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 137 | 301 | $34,275 | $23,957 | 69.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 49 | 197 | $20,919 | $14,753 | 70.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 46 | 215 | $15,065 | $11,292 | 75.0% |
| 94375 | Test to measure rate of airflow | Office | 2022 | 145 | 296 | $20,008 | $7,302 | 36.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 33 | 36 | $7,633 | $5,265 | 69.0% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 118 | 118 | $5,828 | $4,366 | 74.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 56 | 82 | $7,184 | $3,811 | 53.1% |
| 94727 | Test to determine lung volumes using gas dilution or washout | Office | 2022 | 121 | 121 | $4,868 | $3,373 | 69.3% |
| 94200 | Test to measure largest amount of air breathed in an out | Office | 2022 | 145 | 296 | $7,228 | $3,244 | 44.9% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 24 | 24 | $3,347 | $1,928 | 57.6% |
| 94640 | Inhalation treatment for airway obstruction or sputum production | Office | 2022 | 85 | 171 | $2,812 | $1,397 | 49.7% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 16 | 17 | $1,045 | $672.78 | 64.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 109 | 237 | $21,181 | $14,553 | 68.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 50 | 183 | $16,235 | $12,500 | 77.0% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 29 | 113 | $7,110 | $5,688 | 80.0% |
| 94375 | Respiratory diagnostic testing (flow volume loop) | Office | 2021 | 123 | 227 | $6,921 | $5,143 | 74.3% |
About Dr. Noel Totti, MD
Dr. Noel Totti, MD is a Pulmonary Disease healthcare provider based in Hato Rey, Puerto Rico. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/27/2006. The National Provider Identifier (NPI) number assigned to this provider is 1649237181.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Noel Totti, MD has received a total of $10,276 in payments from pharmaceutical and medical device companies, with $1,872 received in 2024. These payments were reported across 468 transactions from 24 companies. The most common payment nature is "Food and Beverage" ($10,257).
As a Medicare-enrolled provider, Totti has provided services to 3,284 Medicare beneficiaries, totaling 5,846 services with total Medicare billing of $244,867. Data is available for 4 years (2020–2023), covering 49 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Hato Rey, PR
- Active Since 04/27/2006
- Last Updated 09/08/2010
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1649237181
Products in Payments
- TRELEGY ELLIPTA (Drug) $1,826
- STIOLTO RESPIMAT (Drug) $737.31
- OFEV (Drug) $687.99
- FASENRA (Biological) $667.37
- DUPIXENT (Biological) $619.57
- TEZSPIRE (Biological) $613.98
- ELIQUIS (Drug) $452.28
- NUCALA (Biological) $437.26
- FASENRA (Drug) $378.49
- SYMBICORT (Drug) $316.80
- BEVESPI AEROSPHERE (Drug) $301.57
- XARELTO (Drug) $267.70
- GLASSIA (Biological) $245.86
- ANORO ELLIPTA (Drug) $243.29
- ANORO (Drug) $230.03
- Xolair (Biological) $217.84
- Esbriet (Biological) $191.60
- OPSUMIT (Drug) $156.32
- Yupelri (Drug) $148.03
- BREO (Drug) $134.87
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.